Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice by Gao, Zhanguo et al.
Butyrate Improves Insulin Sensitivity and Increases
Energy Expenditure in Mice
Zhanguo Gao,
1 Jun Yin,
1 Jin Zhang,
1 Robert E. Ward,
2 Roy J. Martin,
1 Michael Lefevre,
2
William T. Cefalu,
1 and Jianping Ye
1
OBJECTIVE—We examined the role of butyric acid, a short-
chain fatty acid formed by fermentation in the large intestine, in
the regulation of insulin sensitivity in mice fed a high-fat diet.
RESEARCH DESIGN AND METHODS—In dietary-obese
C57BL/6J mice, sodium butyrate was administrated through diet
supplementation at 5% wt/wt in the high-fat diet. Insulin sensi-
tivity was examined with insulin tolerance testing and homeosta-
sis model assessment for insulin resistance. Energy metabolism
was monitored in a metabolic chamber. Mitochondrial function
was investigated in brown adipocytes and skeletal muscle in the
mice.
RESULTS—On the high-fat diet, supplementation of butyrate
prevented development of insulin resistance and obesity in
C57BL/6 mice. Fasting blood glucose, fasting insulin, and insulin
tolerance were all preserved in the treated mice. Body fat content
was maintained at 10% without a reduction in food intake.
Adaptive thermogenesis and fatty acid oxidation were enhanced.
An increase in mitochondrial function and biogenesis was ob-
served in skeletal muscle and brown fat. The type I ﬁber was
enriched in skeletal muscle. Peroxisome proliferator–activated
receptor- coactivator-1 expression was elevated at mRNA and
protein levels. AMP kinase and p38 activities were elevated. In
the obese mice, supplementation of butyrate led to an increase in
insulin sensitivity and a reduction in adiposity.
CONCLUSIONS—Dietary supplementation of butyrate can pre-
vent and treat diet-induced insulin resistance in mouse. The
mechanism of butyrate action is related to promotion of energy
expenditure and induction of mitochondria function. Diabetes
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ecent studies suggest that natural compounds
represent a rich source for small thermogenic
molecules, which hold potential in the preven-
tion and treatment of obesity and insulin resis-
tance. Several natural products, such as resveratrol (1,2),
bile acid (3), and genipin (4), have been reported to
increase thermogenic activities in animal or cellular mod-
els. In the current study, we provide evidence for the
thermogenic activity and therapeutic value of a short-
chain fatty acid, butyric acid, in a mouse model of meta-
bolic syndrome. Butyric acid has four carbons in the
molecule (CH3CH2CH2-COOH) and becomes sodium bu-
tyrate after receiving sodium. Sodium butyrate is a dietary
component found in foods such as cheese and butter. It is
also produced in large amounts from dietary ﬁber after
fermentation in the large intestine, where butyric acid is
generated together with other short-chain fatty acids from
nondigestible carbohydrates, such as nonstarch polysac-
charides, resistant starch, and miscellaneous low-digest-
ible saccharides (5,6). The bioactivities of sodium butyrate
are related to inhibition of class I and class II histone
deacetylases (7). Histone deacetylases regulate gene tran-
scription through modiﬁcation of chromatin structure by
deacetylation of proteins, including histone proteins and
transcription factors. To our knowledge, there is no report
about butyrate in the regulation of insulin sensitivity or
energy metabolism.
Dietary intervention is a potential strategy in the preven-
tion and treatment of metabolic syndrome. Peroxisome pro-
liferator–activated receptor (PPAR)- coactivator (PGC)-1,
a transcription coactivator, is a promising molecular target
in dietary intervention (1,2). PGC-1 controls energy me-
tabolism by interaction with several transcription factors,
e.g., estrogen-related receptor-, nuclear respiratory fac-
tor-1 and -2, PPAR- and -, and thyroid hormone receptor,
that direct gene transcription for mitochondrial biogenesis
and respiration (8). In the muscle, PGC-1 increases
oxidative (type I) ﬁber differentiation and enhances fatty
acid metabolism (9). In brown fat, PGC-1 stimulates
adaptive thermogenesis through upregulation of uncou-
pling protein (UCP)-1 expression (10). A reduction in
PGC-1 function is associated with mitochondrial dys-
function, reduction in fatty acid oxidation, and risk for
insulin resistance or type 2 diabetes (11–14). Dietary
intervention of PGC-1 activity holds promise in the
prevention and treatment of metabolic syndrome. How-
ever, our knowledge is limited in the dietary components
or derivatives that are able to regulate the PGC-1 activity.
In the current report, we provide evidence that sodium
butyrate induced PGC-1 activity in skeletal muscle and
brown fat in mice.
RESEARCH DESIGN AND METHODS
Male C57BL/6J (4 weeks old) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). After 1 week quarantine, the C57BL/6J mice
were fed a high-fat diet (D12331; Research Diets, New Brunswick, NJ), in
which 58% of calories is from fat. All of the mice were housed in the animal
facility with a 12-h light/dark cycle and constant temperature (22–24°C). The
mice had free access to water and diet. All procedures were performed in
accordance with National Institutes of Health guidelines for the care and use
of animals and were approved by the institutional animal care and use
committee at the Pennington Biomedical Research Center.
Sodium butyrate administration. Sodium butyrate (303410; Sigma) was
incorporated into the high-fat diet at 5% wt/wt. Sodium butyrate was blended
into the diet using a food processor at 400 rpm. The sodium butyrate–
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DIABETES, VOL. 58, JULY 2009 1509containing diet was pelleted and stored in a –20°C freezer until usage. On the
supplemented diet, mice could receive sodium butyrate at 5 g  kg
1  day
1 at
the normal daily rate of calorie intake.
Intraperitoneal insulin tolerance. Intraperitoneal insulin tolerance testing
was conducted by intraperitoneal injection of insulin (I9278; Sigma) at 0.75
units/kg body wt in mice after a 4-h fast, as described previously (15).
Nuclear magnetic resonance. Body composition was measured for the fat
content using quantitative nuclear magnetic resonance as previously de-
scribed (15).
Quantitative real-time RT-PCR. Total RNA was extracted from frozen
tissues (kept at 80°C) using Tri-Reagent (T9424; Sigma), as described
previously (16). TaqMan RT-PCR primer and probe were used to deter-
mine mRNA for PGC-1 (Mm00447183_m1), UCP-1 (Mm00494069_m1),
PPAR- (Mm01305434_m1), and carnitine palmitoyltransferase-1b (CPT1b;
Mm00487200_m1). The reagents were purchased from Applied Biosystems
(Foster City, CA). Mouse ribosomal 18S rRNA_s1 (without intron-exon
junction) was used as an internal control. The reaction was conducted with a
7900 HT Fast real-time PCR system (Applied Biosystems).
Metabolic chamber. Energy expenditure, respiratory exchange ratio, spon-
taneous physical movement, and food intake were measured simultaneously
for each mouse with a comprehensive laboratory animal monitoring system
(Columbus Instruments, Columbus, OH) as described previously (15).
Body temperature in cold response. Body temperature was measured in
the cold room with ambient temperature at 4°C. Animals were sedated and
restrained for 30 s during the measurement. A Thermalert model TH-8
temperature monitor (Physitemp, Clifton, NJ) was used with the probe placed
in the rectum at 2.5 cm in depth.
Western blotting. Fresh fat and muscles were collected and frozen imme-
diately in liquid nitrogen. The whole-cell lysate was prepared in a lysis buffer
with sonication as described previously (16). Antibodies and their sources are
myoglobin (sc-25607; Santa Cruz Biotechnology), phosphorylated Akt (threo-
nine 308 [Thr308], no. 9275; Cell Signaling), tubulin (ab7291; Abcam), phos-
phorylated insulin receptor substrate-1 (tyrosine 632 [Tyr632], no. sc-17196;
Santa Cruz Biotechnology), myosin (M8421; Sigma), phosphorylated AMP
kinase (AMPK; Thr172, no. 2531; Cell Signaling), and pP38 (sc-7975; Santa
Cruz Biotechnology). The antibodies to PGC-1 and UCP-1 were from Dr.
Thomas Gettys at our institute (Pennington Biomedical Research Center).
Muscle ﬁber type. The ﬁber types in skeletal muscle were examined using
two methods: succinate dehydrogenase staining for ATPase and immunostain-
ing of type I myosin heavy chain. In the succinate dehydrogenase staining,
midbelly cross-sections of muscle were cut at 8 m in a cryostat (–20°C). After
drying for 5 min at room temperature, the sections were incubated at 37°C for
60 min in incubation solution containing 6.5 mmol/l sodium phosphate
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FIG. 1. Energy metabolism in response to sodium butyrate. Butyrate increased energy expenditure in C57BL/B6 mice. Energy expenditure was
examined using the metabolic chamber at the 1st week and the 10th week on high-fat diet (16 weeks in age). In this study, sodium butyrate was
used at 5% wt/wt in high-fat diet. A: Food intake. Food intake was monitored daily for 5 days at each time point. Average daily food intake (g)
was converted into kilocalories and normalized with body weight (kg) and 24 h. B: Energy expenditure measured as kilocalories per kilogram lean
mass per hour. C: Oxygen consumption measured as milliliters volume oxygen per kilogram lean mass per hour. D: Substrate utilization. This is
expressed by respiratory exchange ratio (RER), which is the volume ratio of oxygen consumed versus CO2 exhaled. E: Body weight (BW). F: Body
fat content in percentage of body weight. This was determined by nuclear magnetic resonance. G: Body muscle content in percentage of body
weight. H: Lipid in feces. Feces were collected in the cages during a 24-h period on high-fat diet at 12 weeks. Total lipids were extracted and
quantiﬁed (P > 0.05, n  5). I: Spontaneous physical activity. The frequency of horizontal movement (X) was shown for day and night at 10 weeks
on a high-fat diet. For A–D, and I, n  8 in the control or butyrate group. For E–G, n  10 in the control or butyrate group. Values are the means 
SE. *P < 0.05, **P < 0.001 by Student’s t test. , Control; f, butyrate.
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1510 DIABETES, VOL. 58, JULY 2009monobasic, 43.5 mmol/l sodium phosphate biphasic, 0.6 mmol/l nitroblue
tetrazolium (74032; Sigma), and 50 mmol/l sodium succinate (14160; Sigma).
The sections were rinsed three times (30 s each time) in 0.9% saline, 5 min
in 15% ethanol, and then mounted with aqueous mounting medium
(DakoCytomation).
Immunohistostaining. Fresh skeletal muscle was collected, embedded in
gum tragacanth mixed with OCT freezing matrix, and quickly frozen in liquid
nitrogen. The tissue slides were obtained through serial cross-section cutting
at 8 m thickness. The slide was blotted with type I myosin heavy-chain
antibody (M8421; Sigma) at 1:200 dilution. After being washed, the slide
was incubated with a biotinylated secondary antibody (BA-2000), and the
color reaction was performed using ABC elite reagent (PK-6101). A
3,3-diaminobenzidine substrate kit (SK-4100) was used to obtain signal for
myosin I.
Hematoxylin and eosin staining. Fresh tissues (brown adipose tissue
[BAT]) were collected at 16 weeks of age after 12 weeks on the sodium
butyrate–containing diet. Tissue was ﬁxed in 10% formalin solution
(HT50–1-2; Sigma). Tissue slides were obtained through serial cross-
section cutting 8 m in thickness and processed with standard procedure.
Histone deacetylase assay and nuclear extract preparation. Histone
deacetylase assay was conducted using a histone deacetylase assay kit
(17-320; Upstate). Brieﬂy, the muscle nuclear extract (10 g) was incubated
with [
3H]acetyl CoA (TRK688; Amersham) radio-labeled histone H4 peptide
(25,000 cpm, as a substrate) at 37°C for 12 h by shaking. Released [
3H]acetate
was measured using a scintillation counter. The nuclear extract was prepared
according to a protocol described previously (17).
Lipids in serum and feces. The serum fatty acids, including butyrate, were
examined using a protocol described elsewhere (18). The detail is presented
in Supplement 1, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-1637/DC1. Fatty acids in feces were
determined using the protocol from a study by Schwarz et al. (19). Triglycer-
ide and cholesterol were measured in whole blood with a Cardiochek portable
test system.
Statistical analysis. Data are the means  SE from multiple samples. All of
the in vitro experiments were conducted at least three times. Student’s t test
or two-way ANOVA was used in the statistical analysis with signiﬁcance set at
P  0.05.
RESULTS
Energy metabolism. We ﬁrst tested butyrate in preven-
tion of dietary obesity. In the diet-induced obesity model,
butyrate supplementation started at the beginning of high-
fat diet feeding. Plain high-fat diet was used in the control
group. Calorie intake was monitored four times in the ﬁrst
10 weeks. After normalization with body weight, calorie
intake was reduced with the increase in age. In the
butyrate group, it was signiﬁcantly higher at all of the time
points (Fig. 1A). Energy expenditure, oxygen consump-
tion, and substrate utilization were monitored using a
metabolic chamber. In the butyrate group, energy expen-
diture and oxygen consumption were elevated at night
(Fig. 1B and C). The respiratory exchange ratio was
reduced during the day and night (Fig. 1D), suggesting an
increase in fatty acid oxidation in response to butyrate.
These data suggest that sodium butyrate may increase
energy expenditure in the diet-induced obesity model.
Body weight and fat content were monitored in this
study. In the control mice, body weight increased from 23
to 40 g after 16 weeks on high-fat diet (Fig. 1E), and fat
content (adiposity) increased from 10 to 35% of body
weight (Fig. 1F). Accordingly, lean mass was reduced from
80 to 65% (Fig. 1G). In the butyrate group, these parame-
ters were not signiﬁcantly changed during the 16 weeks on
high-fat diet (Fig. 1E, F, and G), suggesting that butyrate
prevented diet-induced obesity. Mouse growth was not
inﬂuenced by butyrate because body length was identical
between the two groups. Dietary fat digestion and absorp-
tion in the gastrointestinal tract was examined by measur-
ing fatty acid content in feces. Fat content was identical in
the feces of the two groups (Fig. 1H), suggesting that
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FIG. 2. Insulin sensitivity in butyrate-treated mice. A: Fasting glucose. Tail vein blood was used for glucose assay after 16 h fasting during the
period of high-fat diet feeding. B: Fasting insulin. The insulin level was determined at 16 weeks on high-fat diet in fasting condition with a
Lincoplex kit (MADPK model). C: Intraperitoneal insulin tolerance in butyrate-treated mice. Intraperitoneal insulin tolerance testing was
performed at 12 weeks on high-fat diet (at 16 weeks of age). In A–C, data are the means  SE (n  9). *P < 0.05, **P < 0.001 by Student’s t test.
D: HOMA-IR. After an overnight fast, blood glucose and insulin were measured and used to determine insulin sensitivity through HOMA-IR (IR 
fasting insulin mU/ml  fasting glucose mg/dl  405). Values are the means  SE (n  8 mice). **P < 0.001. E: Insulin signaling. The gastrocnemius
muscle was isolated after insulin (0.75 units/kg) injection in mice for 30 min and used to prepare the whole-cell lysate for immunoblot. The mice
on high-fat diet for 13 weeks were used in the signaling assay. F: Signal quantiﬁcation. The blot signal in E was quantiﬁed and presented after
normalization with protein loading. **P < 0.001 (n  2). IRS, insulin receptor substrate.
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intestinal tract. Spontaneous physical activity was moni-
tored during the day and night in the mice. The data
suggest that physical activity was not reduced by butyrate
(Fig. 1I). Increased activity was observed in the butyrate
group at night. These data suggest that dietary supplemen-
tation with butyrate protected the mice from diet-induced
obesity. This effect is associated with an increase in energy
expenditure and fatty acid oxidation. The food intake and
physical activity suggests that no toxicity was observed for
butyrate in the mice.
Insulin sensitivity. The increase in energy metabolism
suggests that butyrate may protect mice from high-fat
diet–induced insulin resistance. To test this possibility,
systemic insulin sensitivity was analyzed by fasting glu-
cose, fasting insulin, and insulin tolerance. In the control
group, fasting glucose was increased signiﬁcantly after 10
weeks on high-fat diet (Fig. 2A). In the butyrate group, this
increase was not observed (Fig. 2A). Fasting insulin was
50% lower in the butyrate group at 16 weeks on high-fat
diet (Fig. 2B). In the intraperitoneal insulin tolerance test,
the butyrate group exhibited much better response to
insulin at all time points (30, 60, 120, and 180 min) (Fig.
2C). Homeostasis model assessment for insulin resistance
(HOMA-IR) was 60% lower in the butyrate group (Fig. 2D).
These data suggest that insulin resistance was prevented
in the butyrate group. Insulin signaling was examined in
the skeletal muscle lysate with Tyr632 (Y632) phosphor-
ylation of insulin receptor substrate-1 protein and
Thr308 phosphorylation of Akt (Fig. 2E). Both signals
were increased in the butyrate-treated mice (Fig. 2E and
F), suggesting a molecular mechanism of insulin
sensitization.
BAT. The association of increased food intake with ele-
vated energy expenditure led us to study BAT, which is
responsible for adaptive thermogenesis in response to diet
or cold (20–22). Diet-induced thermogenesis reduces obe-
sity in both humans and animals (23). In the butyrate
group, the increase in energy expenditure was observed at
night when mice actively took food (Fig. 1A and B). This
result suggests an increase in thermogenesis. To deter-
mine the thermogenic function, we conducted a cold-
response experiment. Mice were exposed to a cold
environment with an ambient temperature of 4°C for 90
min. Core body temperature was monitored three times by
measuring the rectal temperature. In control mice, body
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FIG. 3. Brown adipose tissue response to sodium butyrate. A: Adaptive thermogenesis in cold environment. Rectum temperature was measured
when the mice were exposed to 4°C ambient temperature in a cold room at 10 weeks on high-fat diet. Details of the procedure are described in
RESEARCH DESIGN AND METHODS. B: Hematoxylin and eosin staining in BAT. The staining was conducted in BAT collected at 13 weeks on high-fat diet.
Photograph was taken at 100 magniﬁcation. C: mRNA expression in BAT. BAT was collected at 13 weeks on high-fat diet. Gene expression was
examined by qRT-PCR. mRNA of PGC-1 and UCP-1 in brown fat of mice treated with butyrate was measured. D: Immunoblot of protein in BAT.
BAT was collected at 13 weeks of butyrate treatment. The whole-cell lysate (100 g) was resolved in SDS-PAGE and blotted with PGC-1 and
UCP-1 antibodies. Data are the means  SE (n  9 mice). *P < 0.05. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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min in the cold (Fig. 3A). In butyrate-treated mice, body
temperature dropped to 35°C transiently at 30 min and
then returned to 36°C for the remainder of the time. These
data suggest that thermogenic function is enhanced in the
butyrate group.
Brown fat is critical for adaptive thermogenesis in mice.
Morphology and gene expression were examined in brown
fat. Compared with the control mice, the size of brown
adipocytes was much smaller in the butyrate group (Fig.
3B), suggesting higher thermogenic activity that leads to
the reduction in fat accumulation. Mitochondrial function
is regulated by gene expression (24). To understand the
molecular basis of the increased thermogenesis, we exam-
ined the expression of two thermogenesis-related genes,
PGC-1 and UCP-1, in BAT. mRNA of both genes was
increased in the butyrate-treated mice (Fig. 3C). The
increase was observed in their proteins in the brown fat
(Fig. 3D). The increased gene expression provides a
molecular basis for enhanced thermogenesis by butyrate
treatment.
Skeletal muscle. To understand the cellular basis of
enhanced fatty acid utilization in the butyrate group, we
assessed muscle ﬁber types. PGC-1 was reported to induce
transformation of skeletal muscle ﬁber from glycolytic type
(type II) into oxidative type (type I) in transgenic mice (9).
Type I ﬁbers are distinct from type II ﬁbers in several
properties (25). Type I ﬁbers (oxidative and slow-twitch
ﬁbers) are rich in mitochondria, red in color, and active in fat
oxidation for ATP biosynthesis. Type II ﬁbers (glycolytic and
fast-twitch ﬁbers) are relatively poor in mitochondrial activ-
ity, lighter in color, and dependent on glycolysis in ATP
production. The butyrate effect on PGC-1 in BAT suggests
that skeletal muscle ﬁbers may be changed by butyrate.
Compared with the control group, the butyrate group
exhibited a deep red color (Fig. 4A). Fiber type analysis
was conducted in the vastus lateralis, gastrocnemius (rich
in glycolytic ﬁbers), and soleus (rich in oxidative ﬁber).
Type I ﬁber was determined with type I myosin heavy-
chain immunohistostaining. The ratio of type I ﬁbers were
increased in all of the skeletal muscles of butyrate-treated
mice (Fig. 4B). The increase was conﬁrmed with a meta-
chromatic dye–ATPase assay, in which the type I ﬁbers
were blue in color (Fig. 4C). To support the change in muscle
morphology, the proteins of type 1 myosin heavy chain and
PGC-1were quantiﬁed in muscle lysate in an immunoblot. A
signiﬁcant increase was observed in both proteins in bu-
tyrate-treated mice (Fig. 4D). Myoglobin (another marker of
oxidative type I ﬁber) was also increased by butyrate (Fig.
4D). A mean value of each protein is presented in Fig. 4D.
These data suggest that the ratio of type I ﬁber was increased
by butyrate in skeletal muscle.
AMPK and p38 activities were examined by their phos-
phorylation status. Their activities may contribute to ele-
vation of PGC-1 protein through enhanced protein
stability (26–28). It was not clear whether this mechanism
was activated by butyrate. To test this possibility, we
examined activity of AMPK and p38 in skeletal muscle. An
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FIG. 4. Oxidative ﬁber in skeletal muscle. A: Vastus lateralis muscle. The tissue was isolated from mice that were fed high-fat diet for 13 weeks.
B: Oxidative ﬁber (type I ﬁbers) in serial cryostat sections of muscle. The muscle tissue slides were made from vastus lateralis, gastrocnemius
(gastr.), and soleus muscle. They were stained with antibody against type I myosin heavy chain for oxidative ﬁbers, as indicated by the brown
color. The photograph was taken at 20 magniﬁcation. C: Succinate dehydrogenase staining of oxidative ﬁbers. The oxidative ﬁbers were stained
in serial cryostat sections of the vastus lateralis and gastrocnemius (gastr.) muscle as indicated by dark blue color in the photomicrograph. D and
E: Quantiﬁcation of proteins in immunoblot. The whole-cell lysate was prepared from muscle tissues and analyzed in an immunoblot. Signals for
PGC-1, type I myosin heavy chain, myoglobin, phosphorylated AMPK (pAMPK), and phosphorylated p38 (pP38) were blotted with speciﬁc
antibodies. A representative blot is shown. Relative signal strength was quantiﬁed for each band and expressed in the bar ﬁgure. Results are the
means  SE (n  8 mice). *P < 0.01, **P < 0.001 (vs. control). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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lysate of butyrate-treated mice (Fig. 4D), suggesting in-
creased activation of the two kinases by butyrate. In the L6
cell line, AMPK and p38 phosphorylation was increased by
butyrate in the cell culture (Fig. 5A), suggesting butyrate is
able to activate AMPK directly. In the same culture,
PGC-1 protein was increased (Fig. 5A). In the liver of
butyrate-treated mice, a similar pattern of changes was
observed in AMPK, p38, and PGC-1 (Fig. 5B). These data
consistently suggest that AMPK and p38 were activated by
butyrate and that their activation may contribute to the
increase in PGC-1 activity.
Mitochondrial function. Mitochondrial function was ex-
amined in skeletal muscle tissue and L6 muscle cells under
butyrate treatment. Fatty acid oxidation was monitored in
gastrocnemius muscle with
14C-labeled palmitic acid. A
200% increase in
14C-labeled CO2 was observed in bu-
tyrate-treated mice (Fig. 6A). Fatty acid oxidation was
associated with expression of PGC-1 target genes, such
as CPT1b and COX-I (cytochrome c oxidase I) (9). Expres-
sion of these two genes was increased in skeletal muscle
of butyrate-treated mice (Fig. 6B and C). The nuclear
receptor PPAR- promotes fatty acid oxidation in skeletal
muscle (29). PPAR- expression was also increased in
butyrate-treated mice (Fig. 6B). In cultured L6 cells, a
similar increase was observed in fatty acid oxidation and
gene expression after butyrate treatment (Fig. 6D and E).
These data consistently support the role of butyrate activ-
ity in the promotion of mitochondrial function.
Histone deacetylase activity in muscle. The butyrate
concentration was analyzed in serum collected from the
butyrate and control groups. In the fasted condition (over-
night fast), the butyrate concentration was 7.23  0.93
g/ml in the butyrate group and 5.71  0.38 g/ml in the
control animals. In the fed condition, the butyrate concen-
tration was 9.40  1.36 g/ml in the butyrate group versus
5.48  0.60 g/ml in the control mice (P  0.05, n 	 5)
(Fig. 6F). The data suggest that dietary supplementation
increased butyrate levels in the blood. It is likely that the
metabolic activity of butyrate is related to inhibition of
histone deacetylase. Sodium butyrate inhibits the class I
and class II histone deacetylases. To test this possibility,
histone deacetylase activity was examined in skeletal
muscle of mice at 16 weeks on high-fat diet (Fig. 6F). The
assay was conducted with nuclear extracts of muscle
samples. Histone deacetylase activity was reduced by 50%
in the butyrate group (Fig. 6G). Trichostatin A (TSA), a
typical histone deacetylase inhibitor, was used as a posi-
tive control in the parallel treatment. Histone deacetylase
activity was decreased in the skeletal muscle of TSA-
treated mice (Supplement 2). These data suggested that
dietary supplementation of butyrate leads to suppression
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eride and cholesterol were examined in the blood. These
lipids were reduced in the butyrate group (Fig. 6H and I).
Treatment of obesity with butyrate. In the prevention
studies, butyrate was administrated together with high-fat
diet during the induction of obesity. To test butyrate in the
treatment of obesity and insulin resistance, we adminis-
trated butyrate to obese mice that had been on a high-fat
diet for 16 weeks. After a 5-week treatment with butyrate,
the obese mice lost 10.2% of their original body weight,
which dropped from 37.6 to 34.4 g (Fig. 7A). In the control
group, body weight increased by 15.8% (from 35.9 to
41.6 g) during the same time period. Consistent with the
change in body weight, fat content was reduced by 10% in
the butyrate group (Fig. 7B). Furthermore, fasting glucose
was reduced by 30% from 131 to 98.6 mg/dl (P  0.016),
HOMA-IR was reduced by 50%, and intraperitoneal insulin
tolerance was improved signiﬁcantly in the butyrate group
(Fig. 7C and D). These data suggest that butyrate is
effective in the treatment of obesity and insulin resistance
in the dietary obese model.
DISCUSSION
Metabolic activities of butyric acid were examined in this
study in diet-induced obese mice. The most important
observation is that butyrate supplementation at 5% wt/wt
in high-fat diet prevented development of dietary obesity
and insulin resistance. It also reduced obesity and insulin
resistance in obese mice. In butyrate-treated mice, the
plasma butyrate concentration was increased, and blood
lipids (triglycerides, cholesterol, and total fatty acids)
were decreased (Fig. 6H–I and Supplement 1). The change
in insulin sensitivity may be a consequence of a reduction
in adiposity in our model. The increase in energy expen-
diture and fatty acid oxidation may be responsible for the
antiobesity effect of butyrate. Butyrate supplementation
did not reduce food intake, fat absorption, or locomotor
activity, suggesting that there was no toxicity from bu-
tyrate. Butyrate was tested at 5 and 2.5% wt/wt in the
high-fat diet in this study. At the lower (2.5% wt/wt)
dosage, similar metabolic activity was observed (Supple-
ment 3). At 5% in the high-fat diet, butyrate increased the
calorie content from 58 to 64.4% in the fat. The increase in
fat calories may not contribute to our observation of the
antiobesity activity for butyrate. A recent study of weight-
loss diets suggests that total calorie intake, not diet
composition, is responsible for weight reduction in hu-
mans (30). At the cellular level, butyrate increased mito-
chondrial respiration, as indicated by the increase in
oxygen consumption and CO2 production. At the molecu-
lar level, increased expression of PGC-1, PPAR-, and
CPT1b may be involved in the stimulation of mitochon-
drial function by butyrate.
The current study indicates that in vivo butyrate is a
novel activator of PGC-1. PGC-1 activity may be regu-
lated by butyrate at three levels. PGC-1 expression was
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tion was observed in brown fat, skeletal muscle, and liver
in butyrate-treated mice. It may be a result of increased
mRNA expression or extended half-life of the PGC-1
protein. The change in protein stability is supported by the
activities of AMPK and p38 in tissues and cells after
butyrate treatment. These kinases phosphorylate the
PGC-1 protein and inhibit its degradation (27,28,31–34).
As a transcriptional coactivator, PGC-1 transcription
activity may be induced by phosphorylation, which leads
to removal of a suppressor protein (p160 myb) that is
associated with PGC-1 in the basal condition (35). P38
acts downstream of AMPK in the phosphorylation of
PGC-1 (36). Therefore, AMPK may increase PGC-1
phosphorylation through direct and indirect (p38) mecha-
nisms. It is not clear how AMPK is activated by butyrate.
Butyrate may act through induction of AMP levels in cells
from increased consumption of ATP. It was reported that
butyrate increases ATP consumption (37). Induction of
PGC-1 activity may be a molecular mechanism by which
butyrate stimulates mitochondrial function.
Inhibition of histone deacetylase may contribute to
increased mRNA expression of PGC-1, PPAR-, and
CPT1b. Histone deacetylase inhibition promotes gene ex-
pression through transcriptional activation, which is de-
termined by gene promoter activity. Promoter activation
requires histone acetylation, which opens chromatin DNA
to the general transcription factors for transcription initi-
ation and mRNA elongation. Histone deacetylase inhibits
gene promoter activity through deacetylation of histone
proteins. In the presence of butyrate, promoter inhibition
is prevented by butyrate suppression of histone deacety-
lase. Histone deacetylase suppression will enhance his-
tone acetylation. This chromatin modiﬁcation may occur
in the gene promoters for PGC-1, PPAR-, and CPT1b for
the upregulation of gene transcription.
Butyrate induces type I ﬁber differentiation in skeletal
muscle. In skeletal muscle cells, inhibition of histone
deacetylase enhances myotube differentiation in vitro (28–
30) and protects muscle from dystrophy in vivo (29–31). In
transgenic mice, knockout of class II histone deacetylases
was shown to promote differentiation of type I (oxidative)
ﬁbers in skeletal muscle (32). This is consistent with our
data that type I ﬁber was increased by butyrate, which
inhibits histone deacetylase activities in the skeletal
muscle of butyrate-treated mice. TSA, a typical histone
deacetylase inhibitor, was tested in parallel treatment with
butyrate. TSA exhibited activity similar to that of butyrate
in mice (Supplement 2). TSA prevented dietary obesity,
insulin resistance, and increased the type I ﬁber in the
skeletal muscle. The activity was associated with elevation
of PGC-1 protein. The current study suggests that the
metabolic activities of butyrate may be dependent on the
inhibition of histone deacetylase.
In summary, dietary supplementation of butyrate can
prevent and treat diet-induced obesity and insulin resis-
tance in mouse models of obesity. These activities of
butyrate are similar to those of resveratrol (1,2). The
mechanism of butyrate action is related to promotion of
energy expenditure and induction of mitochondrial func-
tion. Stimulation of PGC-1 activity may be a molecular
mechanism of butyrate activity. Activation of AMPK and
inhibition of histone deacetylases may contribute to the
PGC-1 regulation. Butyrate and its derivatives may have
potential application in the prevention and treatment of
metabolic syndrome in humans.
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